Spotlight Therapeutics

Spotlight Therapeutics is a for-profit corporate entity registered in SAM.gov, specializing in advanced biotechnology and gene editing solutions focused on developing innovative therapeutic interventions. The company appears to be developing targeted gene editing technologies, particularly in the realm of cancer treatment and genetic disease research, utilizing its proprietary Targeted Active Gene Editor (TAGE) platform. Registered since July 2022, Spotlight Therapeutics has established itself as a research-driven organization committed to creating novel biologic treatments that address challenging medical conditions with limited existing therapeutic options.

The company has secured federal grant awards primarily from the National Cancer Institute, with a notable prime grant (R44CA287699) focused on developing TAGE-201, an intratumoral antibody-directed CRISPR gene editor designed for anal cancer immunotherapy. This grant, awarded in September 2023, aims to create a treatment that can knockout ADAR in tumor microenvironment immune cells to enhance immune checkpoint blockade effectiveness. Spotlight Therapeutics has also engaged in collaborative sub-grant work with the University of Wisconsin System, including projects targeting genetic eye disorders like Best disease. These grants involve developing advanced gene editing treatments using non-viral CRISPR genome editing platforms, with research extending to preclinical studies in large animal models like pigs and non-human primates. The company's work demonstrates a strategic approach to developing potentially transformative gene editing therapies across different disease domains, with a clear focus on translational research that bridges laboratory discoveries with potential clinical applications.